Caro Pharma SRL
Caro Pharma reported total assets of 593,057 € at the end of the 2025 financial year (annual accounts filed with the NBB on 26 Jun 2026).
The score of Caro Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -41 % Total assets -27 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Caro Pharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | −26,056 € | ||||
| Equity | 154,269 € | ||||
| Cash | 29,891 € | ||||
| EBITDA | 78,496 € | ||||
| Total assets | 593,057 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 26 Jun 2026
- Year ended 31 Dec 2024filed on 29 Aug 2025
- Year ended 31 Dec 2023filed on 14 Jun 2024
- Year ended 31 Dec 2022filed on 22 Aug 2023
- Year ended 31 Dec 2021filed on 15 Jul 2022
Caro Pharma's financial analysis
- Solvency26.0%sector median: 40.1%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Caro Pharma
Caro Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0899.338.864
- VAT number
- BE0899338864
- Peppol
- Registered · 0208:0899338864 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 17 Jul 2008
- Registered office
- 6560 Erquelinnes
- Latest accounts
- 2025 · filed on 26 Jun 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Caro Pharma (SRL) has been based in Erquelinnes since 2008, active in: retail sale of pharmaceutical products. For 2025, it reports a net loss of 26,056 € and equity of 154,269 €; its revenue is not published. Its solvency stands at 26.0%, below the median of its sector (40.1%).
Companies similar to Caro Pharma
Companies in the same business, of comparable size and area, outside its group.
- Pharmacie DE Neef - Duez Retail sale of pharmaceutical products Mons · balance sheet 181,026 €
- Emanuel - VAN Hauwermeiren Retail sale of pharmaceutical products Dendermonde · balance sheet 588,306 €
- Apotheek Godilo Retail sale of pharmaceutical products Wevelgem · balance sheet 608,404 €
- Esperanto Retail sale of pharmaceutical products Ledegem · balance sheet 573,018 €
- Maudens Jeroen Retail sale of pharmaceutical products Sint-Genesius-Rode · balance sheet 633,969 €
- Farmadec Retail sale of pharmaceutical products Asse · balance sheet 554,731 €
- Vereenooghe OST Retail sale of pharmaceutical products Ostend · balance sheet 553,755 €
- Antwer Retail sale of pharmaceutical products Wervik · balance sheet 548,543 €
Frequently asked questions about Caro Pharma
What is the revenue of Caro Pharma?
Caro Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Caro Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0899338864 for Caro Pharma, if the company is VAT-registered. Its company number (CBE) is 0899.338.864.
Where is the registered office of Caro Pharma?
According to the CBE register, the registered office of Caro Pharma is in 6560 Erquelinnes.
What is the equity of Caro Pharma?
At the close of the 2025 financial year, the equity of Caro Pharma amounts to 154,269 €, a solvency of 26.0% of total assets.
Who manages Caro Pharma?
The register lists 1 active mandates at Caro Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Caro Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →